Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway.

MLA

Xie, Ya-Jia, et al. “Chelidonine Selectively Inhibits the Growth of Gefitinib-Resistant Non-Small Cell Lung Cancer Cells through the EGFR-AMPK Pathway.” Pharmacological Research, vol. 159, Sept. 2020, p. 104934. EBSCOhost, https://doi.org/10.1016/j.phrs.2020.104934.

APA

Xie, Y.-J., Gao, W.-N., Wu, Q.-B., Yao, X.-J., Jiang, Z.-B., Wang, Y.-W., Wang, W.-J., Li, W., Hussain, S., Liu, L., Leung, E. L.-H., & Fan, X.-X. (2020). Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway. Pharmacological Research, 159, 104934. https://doi.org/10.1016/j.phrs.2020.104934

Chicago

Xie, Ya-Jia, Wei-Na Gao, Qi-Biao Wu, Xiao-Jun Yao, Ze-Bo Jiang, Yu-Wei Wang, Wen-Jun Wang, et al. 2020. “Chelidonine Selectively Inhibits the Growth of Gefitinib-Resistant Non-Small Cell Lung Cancer Cells through the EGFR-AMPK Pathway.” Pharmacological Research 159 (September): 104934. doi:10.1016/j.phrs.2020.104934.